"We are delighted that Brixadi is now available to people with opioid use disorder in the US. With an estimated six million people with OUD and 80,000 deaths each year related to opioid overdoses, it is critically important to provide people with OUD access to new effective treatment options that can support their long-term recovery," says Dr.
Brixadi is formulated based on
OUD is a complex and potentially life-threatening condition with a significant negative impact on the individual, their families, and society. The US prevalence of OUD is estimated to be between 6-7 million people2; of these approximately 3 million are diagnosed with OUD, with about half receiving medical treatment.3,4
For more information
Tel. +46 (0)46 286 46 92
fredrik.tiberg@camurus.com
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com
About Brixadi™
Brixadi (buprenorphine) extended-release injection for subcutaneous use is indicated for the treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine. Brixadi should be used as part of a complete treatment plan that includes counselling and psychosocial support.
The product is available through a restricted distribution program known as the Brixadi REMS Program and is only administered by healthcare professionals. Brixadi is administered subcutaneously as a small volume injection (0.16-0.64 mL) in the buttock, thigh, stomach, or upper arm, and does not require refrigeration.
Brixadi is the US trademark for
The product rights to Brixadi in
Brixadi was approved by the
About
References
- Brixadi Prescribing Information
- Keyes KM, et al. Drug Alc. Dep. Reports 2022.
CDC , Opioid Use Disorder: https://www.cdc.gov/dotw/opioid-use-disorderSymphony Health data- Press release
23 May, 2023 :Camurus announces FDA approval of Brixadi™ for the treatment of moderate to severe opioid use disorder
The information was submitted for publication at
https://news.cision.com/camurus-ab/r/camurus-announces-us-launch-of-brixadi--for-the-treatment-of-moderate-to-severe-opioid-use-disorder-,c3829833
https://mb.cision.com/Main/13456/3829833/2275232.pdf
(c) 2023 Cision. All rights reserved., source